INSYNC GLOBAL TITANS FUND
Attached is our most recently updated Fund Review on the Insync Global Titans Fund.
We would like to highlight the following:
-
The Global Titans Fund invests in a concentrated portfolio of 15-30 stocks, targeting exceptional, large cap global companies with a strong focus on dividend growth and downside protection.
-
The Fund's unit price increased by -3.00% in March. Key positive contributors for the month came from our holdings in BNY Mellon, British American Tobacco, Baxter and Oracle. The main negative contributors were DirecTV, Reckitt Benckiser, BSkyB and GlaxoSmithKline. The strengthening in the Australian dollar against the major currencies during the month was also a negative contributor. The Fund continues to have no foreign currency hedging in place.
-
Portfolio selection is driven by a core strategy of investing in companies with sustainable growth in dividends, high returns on capital, positive free cash flows and strong balance sheets.
-
Emphasis on limiting downside risk is through extensive company research, the ability to hold cash and long protective index put options.
For further details on the Fund, please do not hesitate to contact us.
Sean Webster
Research Manager
Australian Fund Monitors
Insync Global Titans Fund AFM Review - March 2014 (pdf format)
